Antisense inhibition of Fas mediated signaling
AssigneeIsis Pharmaceuticals, Inc.
InventorsNicholas M. Dean, Eric G. Marcusson
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.
Claims39
An antisense compound up to 30 nucleobases in length targeted to a nucleic acid molecule encoding Fas, wherein said antisense compound specifically hybridizes with said nucleic acid molecule and inhibits the expression of Fas and wherein said antisense compound has a sequence comprising at least an 8 nucleobase portion of SEQ ID NO:
- 11, 12, 14, 15, 16, 17, 19, 20, or 21.
An antisense compound 8 to 30 nucleobases in length targeted to the coding region of a nucleic acid molecule encoding Fas, wherein said antisense compound inhibits the expression of said Fas and has a sequence comprising SEQ ID NO:
- 6, 7, 8, or 10.
An antisense compound targeted to a nucleic acid molecule encoding Fas, wherein said antisense compound specifically hybridizes with said nucleic acid molecule and inhibits the expression of Fas and wherein said antisense compound has a sequence consisting of SEQ ID NO:
- 5 or 13.
Dependencies are inferred from the claim text.